

A Possible Case of Filgrastim-induced Death

Vinay P^{*1}, Krishna S N¹, Narayana G², Jaffar S², Dixon T³

¹Pharm.D Intern, Department of Pharmacy Practice, ² Assistant Professor, ³ Head of Department of Pharmacy Practice

Raghavendra Institute of Pharmaceutical Education & Research, Anantapur, Andhra Pradesh

Submitted: 21-07-2012

Accepted: 20-02-2013

This is a case report focusing on a 50 year old woman's death possibly due to Filgrastim. Filgrastim is considered to be a drug of choice in neutropenic cases. But in this case, Filgrastim has developed several severe adverse drug reactions resulting into the death of patient. Naranjo's Causality Assessment Algorithm was used to assess the cause of death & the algorithm indicated Filgrastim as a possible cause of death.

Keywords: Filgrastim-Induced Death, Drug-Induced Neutropenia & Granulocyte-Colony Stimulating Factor

INTRODUCTION

Commercially available Granulocyte-Colony Stimulating Factor (G-CSF) preparations have significantly improved the quality of life (QoL) of patients with neutropenia internationally.¹ This report summarizes the development of sore throat, breathlessness (dyspnoea), tachycardia & wheezing sound in chest associated with the use of Filgrastim which finally lead to patient's death.

CASE REPORT

A 50 year old woman was admitted in one of the private hospitals in Maharashtra, with following chief complaints;

- Diffused scaly lesions over the exterior surface of right forearm,
- Similar kind of lesions over the sun-exposed areas of face & lips &
- Black colored discoloration of skin.

On local examination, the skin of the patient was observed to be dry over the lesions with the presence of extensive scaling & patient was unable to open her mouth freely due to presence of sub-mucosal fibrosis (due to betel nuts chewing habit) over buccal region. On the basis of this data, a preliminary/provisional diagnosis was done as *exposure dermatitis & drug hypersensitivity*. The past medical & medication history of patient were asthma since 18 years & the patient was on unknown anti-asthmatic medications. There was no past medical history of cancer. Clinical laboratory tests

(hematological tests) were carried out, which revealed that there was a gradual decrease in the neutrophil count (21.2%) & total count (500cells/mm³) & increase in the Erythrocyte Sedimentation Rate (98mm/hr). On the basis of these clinical laboratory values a final diagnosis was then made as *Drug-induced neutropenia*. Identification of drug/s which induced *neutropenia* was not done. A 300 mcg prefilled syringe of Filgrastim was administered subcutaneously once daily, for 4 days to treat *drug-induced neutropenia*. Other drugs like ceftriaxone, amikacin, liquid paraffin lotion, and chlorhexidine mouthwash were also given to treat lesions & sub-mucosal fibrosis respectively.

On very next day (day 2) of the treatment, patient complained of having sore throat, throat pain & fever. On day 3, she developed breathlessness (dyspnoea), tachycardia & drowsiness along with continuing sore throat & throat pain. On examining lungs, wheezing sounds from the chest were heard. On day 4, patient's daughter reported patient's restlessness which on observation was found to be severe seizure attacks with froth coming out of her mouth followed by cardiac arrest. On examination, she was found to be unconscious, her pulse was not palpating, pupils were not dilated & not reacting to light, no heartbeats & no breathing sounds were heard. Cardio-Pulmonary Resuscitation (CPR) was tried on the patient by starting chest compressions with ambu-bag (at the rate of 30:2 breaths) to save her life. CPR was given for around 20-25 minutes (6 times). Along with CPR, Intravenous (IV) bolus injections of atropine – 1mg/ml (10 ampoules) & adrenaline – 1mg/ml (2 ampoules) were also administered. In spite of all the above rescue methods according to Advanced Cardiac/Cardiovascular Life Support (ACLS) protocols,^{2,3} the patient could not survive and was medically declared dead.

Address for Correspondence:

Vinay Gorakhnath Pawar, PharmD Intern, B-2/112, Niligiri Building, Atmaram Nagar, Lokgram Complex, Netivali Road, Kalyan (East), Dist. Thane – 421306. Maharashtra,

Email: vinaypharmd@gmail.com

DISCUSSION

In this case, *drug-induced neutropenia* was diagnosed & treated on the basis of clinical laboratory investigations other than Absolute Neutrophil Count (ANC) which is a main key for diagnosing neutropenia.⁴ Furthermore the patient was treated with Filgrastim without identifying the drug/s that caused neutropenia. Filgrastim is considered to be a drug of choice in neutropenic cases.^{1,5} But in this case, development of sore throat, breathlessness (dyspnoea), tachycardia & wheezing sound in chest might have been triggered due to filgrastim, as sore throat was observed as an adverse drug reaction (ADR) or an undesirable effect in some of the randomized clinical trials conducted on Filgrastim & the other effects (dyspnoea, tachycardia & wheeze) are given under the “WARNING” column of Filgrastim as serious allergic reactions.⁶⁻⁸ Secondly, as the patient had a past medical history of asthma, more care should have been taken in prescribing filgrastim to the patient because of the possibility of these systemic allergic-like reactions. In one of a randomized, open-labelled, multi-centric study, patients with severe allergic history (seasonal/recurrent asthma) were excluded from their study due to the above reasons.⁹ Taking all this information into consideration, a causality assessment of death was done by using Naranjo's Causality Assessment Algorithm¹⁰ which indicated filgrastim as a possible cause of death with Naranjo score = 3.

CONCLUSION

This case report accentuates the importance of collecting complete data of patient's history such as; past medical history, past medication history, current clinical laboratory tests, etc. before initiating any treatment. Also monitoring, reporting & management of ADRs are necessary in order to avoid such types of severe events.

ACKNOWLEDGEMENTS

I would like to give thanks to my colleagues & my professors for guiding me in assessing the causal relationships of drugs & their effects. I would like to declare that there is **no conflict of interest** of any of the authors of this article.

REFERENCES

1. Dale D.C, Bolyard A.A, Schwinzer B.G. The severe chronic neutropenia international registry: 10-year follow-up report. Supportive Cancer Therapy 2005; 3(4):220-31.
2. Neumar R.W, Otto C.W, Link M.S. Adult advanced cardiovascular life support: 2010 American heart cardiovascular care association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010; 122:729-67.
3. Varon J, Fromm R.E, Vallejo-Manzur F. Advanced cardiac life support algorithms: changes and current American heart association recommendations. Hospital Physician 2002; 35-46.
4. Provan D, Singer C.R.J, Baglin T, Lilleyman J. Oxford handbook of clinical haematology. Oxford University Press. 2nd edition 2004; 16,136.
5. Hassan B.A.R, Yusoff Z.B.M, Othman S.B. Filgrastim and antibiotics treatment reduces neutropenia severity in solid cancer patients. Asian Pacific J Cancer Prev 2009; 10:641-4.
6. Clinical Pharmacology, Filgrastim, Available at: <https://www.clinicalpharmacology.com/Forms/Monograph/monograph.aspx?cpnum=246&sec=monadve&h=647973706e6561> (Assessed on 16/07/2011).
7. Package inserts. Neupogen (Filgrastim). Thousand Oaks, California: Amgen Manufacturing, Limited, Inc., March 2010.
8. Package inserts. Nugraf (Filgrastim). Shameerpet, Hyderabad, Andhra Pradesh: Zenotech Laboratories Limited, Version CF/01-06.
9. Thierry F, Jean-Luc H, Frederic M. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial. Blood 1999; 94(4):1218-25.
10. Naranjo C.A, Busto U, Seliers E.M. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2):239-245.